timepoint, samples demonstrated a significantly greater mean of available space occupied by bone (23.33 ± 3.4% vs 14.35 ± 3.72%; p<0.01). When bone and scaffold were considered together, there was no significant difference in mean space occupancy (6-Week: 56.86 ± 5.88%, 3-Week: 63.27 ± 12.98%; p=0.43), suggesting a stable rate of scaffold degradation/osseous remodeling over time.
CONCLUSION: 3DBC scaffolds composed of β-TCP are capable of inducing bone growth in an undisturbed osseous environment. This osteogenic influence is continually exerted over time, necessitating longer-term follow-up to determine the temporality of the bone-forming capacity of this tissue engineering construct.
*Christopher D Lopez and Jonathan M Bekisz contributed equally to this work. The objective of this study was to test the osteogenic capacity of dipyridamoleloaded, 3D-printed bioactive ceramic (3DPBC) scaffolds utilizing a translational, skeletallymature, large animal calvarial defect model.
Dipyridamole Enhances Osteogenesis of 3D-Printed Bioactive Ceramic Scaffolds in Calvarial Defects

METHODS:
Custom 3DPBC scaffolds designed to present lattice-based porosity only towards the dural surface were either coated with collagen (control) or coated with collagen and immersed in a 100 µM concentration dipyridamole (DIPY) solution. Sheep (n=5) were subjected to 2 ipsilateral trephine-induced (11 mm diameter) calvarial defects. Either a control or a DIPY scaffold was placed in each defect and the surgery was repeated on the contralateral side 3 weeks later. Following sacrifice, defects were evaluated through microcomputed tomography and histologic analysis for bone, scaffold, and soft tissue quantification throughout the defect. Parametric and non-parametric methods were utilized to determine statistical significance based on data distribution.
RESULTS:
No exuberant or ectopic bone formation was observed and no histologic evidence of inflammation was noted within the defects. Osteogenesis was higher in DIPY-coated scaffolds compared to controls at 3 weeks (p=0.013) and 6 weeks (p=0.046) in vivo. When bone formation was evaluated as a function of defect radius, average bone formation was higher for DIPY relative to control scaffolds at both time points (significant at defect central regions at 3 weeks and at margins at 6 weeks; p=0.046 and p=0.031, respectively).
CONCLUSION:
Dipyridamole significantly improves the calvarial bone regeneration capacity of 3D-printed bioactive ceramic scaffolds. The most significant difference in bone regeneration was observed centrally within the interface between the 3DPBC scaffold and the dura mater.
